Versant Side Fund IV, L.P. 4
4 · Oyster Point Pharma, Inc. · Filed Nov 4, 2019
Insider Transaction Report
Form 4
Versant Venture Capital VI, L.P.
10% Owner
Transactions
- Conversion
Common Stock, par value $0.001 per share
2019-11-04+1,654,359→ 1,974,798 total(indirect: See footnotes) - Conversion
Series B Convertible Preferred Stock
2019-11-04−566,158→ 0 total(indirect: See footnote)→ Common Stock, par value $0.001 per share (566,158 underlying) - Conversion
Common Stock, par value $0.001 per share
2019-11-04+10,420→ 12,438 total(indirect: See footnotes) - Purchase
Common Stock, par value $0.001 per share
2019-11-04$16.00/sh+27,500$440,000→ 2,002,298 total(indirect: See footnotes) - Purchase
Common Stock, par value $0.001 per share
2019-11-04$16.00/sh+125,000$2,000,000→ 2,561,888 total - Conversion
Series A Convertible Preferred Stock
2019-11-04−1,941,500→ 0 total→ Common Stock, par value $0.001 per share (1,941,500 underlying) - Conversion
Series B Convertible Preferred Stock
2019-11-04−495,388→ 0 total→ Common Stock, par value $0.001 per share (495,388 underlying) - Conversion
Common Stock, par value $0.001 per share
2019-11-04+1,941,500→ 1,941,500 total - Conversion
Common Stock, par value $0.001 per share
2019-11-04+566,158→ 566,158 total(indirect: See footnote) - Purchase
Common Stock, par value $0.001 per share
2019-11-04$16.00/sh+437,500$7,000,000→ 1,003,658 total(indirect: See footnote) - Conversion
Series A Convertible Preferred Stock
2019-11-04−10,420→ 0 total(indirect: See footnotes)→ Common Stock, par value $0.001 per share (10,420 underlying) - Conversion
Series A Convertible Preferred Stock
2019-11-04−1,654,359→ 0 total(indirect: See footnotes)→ Common Stock, par value $0.001 per share (1,654,359 underlying) - Conversion
Common Stock, par value $0.001 per share
2019-11-04+495,388→ 2,436,888 total
Footnotes (6)
- [F1]These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- [F2]Shares held by Versant Side Fund IV, L.P. ("Versant Side Fund IV").
- [F3]Shares held by Versant Venture Capital IV, L.P. ("Versant IV").
- [F4]Versant Ventures IV, LLC ("Versant Ventures IV") is the sole general partner of each of Versant IV and Versant Side Fund IV. Each of Brian G. Atwood, Samuel D. Colella, Ross A. Jaffe, William J. Link, Rebecca B. Robertson, Bradley J. Bolzon, Charles M. Warden, Kirk G. Nielsen, Thomas F. Woiwode and Robin L. Praeger, as managing members of Versant Ventures IV, may be deemed to share voting and dispositive power over the shares held by Versant IV and Versant Side Fund IV; however, they each disclaim beneficial ownership of such securities, except to the extent of their pecuniary interests therein. William J. Link is a director of the Issuer and, accordingly, files separate Section 16 reports.
- [F5]Shares directly held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Bradley J. Bolzon, Jerel C. Davis, Kirk G. Nielsen, Robin L. Praeger and Thomas F. Woiwode, and as November 1, 2019 Clare Ozawa, as managing members of Versant Ventures VI GP-GP, may be deemed to share voting and dispositive power over the shares held by Versant VI; however, they each disclaim beneficial ownership of such securities, except to the extent of their pecuniary interests therein.
- [F6]Shares held by Versant Vantage I, L.P. ("Versant Vantage"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. Each of Bradley J. Bolzon, Jerel C. Davis, Clare Ozawa, Robin L. Praeger and Thomas F. Woiwode, as managing members of Versant Vantage I GP-GP, may be deemed to share voting and dispositive power over the shares held by Versant Vantage; however, they each disclaim beneficial ownership of such securities, except to the extent of their pecuniary interests therein. Clare Ozawa is a director of the Issuer and, accordingly, files separate Section 16 reports.